Doç. Dr. NECMİ EREN

Yayın Ağı

Makaleler 70

1. The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease

Ozcan S. G., EREN N., Dincer M. T., Atli Z., BOLAYIRLI İ. M., ERGÜL M., et al.

BMC Nephrology , cilt.26, sa.1, 2025 (SCI-Expanded, Scopus)

2. The role of complement C3 deposition in ANCA-associated glomerulonephritis: a registry-based study of clinical, histopathological, and prognostic insights

Uzun S., Gok Oguz E., YILDIZ A., DERİCİ Ü., Cankaya E., Sahin G., et al.

BMC Nephrology , cilt.26, sa.1, 2025 (SCI-Expanded, Scopus)

3. Association of tumor necrosis factor receptors 1 and 2 with kidney volume and function in patients with autosomal dominant polycystic kidney disease

Ozcan S. G., ERGÜL M., EREN N., Tunc S., ERSOY D. Y., DİNÇER M. T., et al.

Clinical Nephrology , cilt.104, sa.5, ss.303-309, 2025 (SCI-Expanded, Scopus)

4. SON DÖNEM BÖBREK HASTALIĞI OLAN HASTALARDA EREKTİL DİSFONKSİYON VE ASİMETRİK DİMETİL ARGİNİN DÜZEYLERİ ARASINDAKİ İLİŞKİ

Can B., bek s. g., ergül M., batman a., Eren N., Okyay R. A., et al.

Acta Medica Nicomedia , cilt.8, sa.2, ss.133-139, 2025 (TRDizin)

5. Relationship Between Pulse Wave Velocity and Cognitive Impairment in Kidney Transplant Recipients

Soyer A. K., EREN N., Özcan Ş. G., ERGÜL M., Yıldız N., Bek S. G., et al.

Experimental and Clinical Transplantation , cilt.23, sa.6, ss.400-405, 2025 (SCI-Expanded, Scopus)

6. Development and validation of the thirst distress scale for patients with autosomal dominant polycystic kidney disease

Ozcan S. G., Bek S. G., EREN N., Atlı Z., YILDIZ A., KOÇYİĞİT İ., et al.

Journal of Nephrology , cilt.38, sa.5, ss.1479-1481, 2025 (SCI-Expanded, Scopus)

7. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy

Barratt J., Barbour S., Brenner R., Cooper K., Wei X., EREN N., et al.

Journal of the American Society of Nephrology , cilt.36, sa.4, ss.679-687, 2025 (SCI-Expanded, Scopus)

8. Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report

SEYAHİ N., KOÇYİĞİT İ., EREN N., Tonbul H. Z., Tatar E., Yılmaz Z., et al.

Turkish Journal of Nephrology , cilt.34, sa.2, ss.141-148, 2025 (ESCI, Scopus, TRDizin)

9. Clinical and histopathological characteristics of primary focal segmental glomerulosclerosis in Turkish adults

KURULTAK İ., Gungor O., Ozturk S., Dirim A. B., EREN N., Yenigün E., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded)

10. Biopsy-proven BK virus nephropathy in renal transplant recipients: A multi-central study from Turkey (BK-TURK STUDY)

Gungor O., Dheir H., Islam M., Toz H., YILDIZ A., Sinangil A., et al.

CLINICAL NEPHROLOGY , cilt.102, ss.202-211, 2024 (SCI-Expanded, Scopus)

11. Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis

ARTAN A. S., MİRİOĞLU Ş., Hocaoğlu R. H., Turgutalp K., GÜLLÜLÜ BOZ S. E., EREN N., et al.

BMC nephrology , cilt.25, sa.1, ss.327, 2024 (SCI-Expanded, Scopus)

12. Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: a registry analysis

Mirioglu S., Cebeci E., Yazici H., DERİCİ Ü., Sahin G., ÇOBAN G., et al.

CLINICAL KIDNEY JOURNAL , cilt.17, sa.8, 2024 (SCI-Expanded, Scopus)

13. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

Lafayette R., Barbour S., Israni R., Wei X., EREN N., Floege J., et al.

Kidney International , cilt.105, sa.6, ss.1306-1315, 2024 (SCI-Expanded, Scopus)

14. Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?

Cetinkaya H., GÜRSU M., Yazici H., Cebeci E., EREN N., ALTIPARMAK M. R., et al.

Journal of Nephrology , cilt.37, sa.4, ss.923-932, 2024 (SCI-Expanded, Scopus)

15. WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL

Barratt J., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

KIDNEY INTERNATIONAL REPORTS , cilt.9, sa.4, ss.174, 2024 (Scopus)

16. Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2022 Turkish Society of Nephrology Registry Report

SEYAHİ N., KOÇYİĞİT İ., EREN N., Tonbul H. Z., Tatar E., Yilmaz Z., et al.

Turkish Journal of Nephrology , cilt.33, sa.2, ss.134-139, 2024 (ESCI, Scopus, TRDizin)

17. WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

Barratt J., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

KIDNEY INTERNATIONAL REPORTS , cilt.9, sa.4, ss.169-170, 2024 (Scopus)

18. WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL

Barratt J., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

KIDNEY INTERNATIONAL REPORTS , cilt.9, sa.4, ss.174-175, 2024 (Scopus)

19. WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

Lafayette R., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

KIDNEY INTERNATIONAL REPORTS , cilt.9, sa.4, ss.173-174, 2024 (Scopus)

20. A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy

Lafayette R., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

Future Rare Diseases , cilt.4, sa.1, 2024 (Scopus)

21. Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

ORUÇ A., ŞUMNU A., Turkmen A., Basturk T., Cebeci E., TURGUTALP K., et al.

RENAL FAILURE , cilt.46, sa.1, 2024 (SCI-Expanded, Scopus)

22. eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefIgArd Phase 3 Trial

Lafayette R. A., Kristensen J., Stone A. M., Floege J., Tesar V., Trimarchi H., et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , cilt.34, sa.11S, ss.8, 2023 (Scopus)

23. New Biomarkers to Quantify Fabry Disease Activity

Ozcan S. G., Eren N., Dincer M. T., Ergul M., Özer H., Turkmen K., et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN , cilt.34, sa.11S, ss.953, 2023 (Scopus)

24. Thirst intensity survey in ADPKD patients

Gokcay Bek S., Yıldız N., Islam M., Ergul M., Sarıoglu I., Guven Taymez D., et al.

CLINICAL AND EXPERIMENTAL NEPHROLOGY , cilt.27, sa.10, ss.819-827, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

Lafayette R., Kristensen J., Stone A., Floege J., Tesař V., Trimarchi H., et al.

The Lancet , cilt.402, sa.10405, ss.859-870, 2023 (SCI-Expanded, Scopus)

26. Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study

MİRİOĞLU Ş., KAZANCIOĞLU R., Cebeci E., EREN N., Sakaci T., Alagoz S., et al.

NEPHRON , cilt.147, sa.7, ss.392-400, 2023 (SCI-Expanded, Scopus)

27. Clinical Correlation of Histopathological Classification, Scoring, and Grading in Amyloid Nephropathies: Single-Center Experience

YAPRAK BAYRAK B., VURAL Ç., TEKE K., ERGÜL M., EREN N.

Kocaeli Üniversitesi Sağlık Bilimleri Dergisi , cilt.9, sa.2, ss.120-129, 2023 (TRDizin)

28. #5718 ASSOCIATION OF MULTIPLE PLASMA BIOMARKER LEVELS WITH KIDNEY DISEASE ACTIVITY IN FABRY DISEASE

Özcan Ş. G., Atli Z., Eren N., Dincer M. T., Turkmen K., Ozer H., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.38, sa.Supplement_1, ss.635718, 2023 (Scopus)

29. #3093 PROGNOSTIC FACTORS AND VALIDATION OF THE HISTOLOGIC CHRONICITY SCORE FOR C3 GLOMERULOPATHY: A REGISTRY ANALYSIS

Mirioglu S., Cebeci E., Yazici H., Derici U., Sahin G. M., Eren N., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.38, sa.Supplement_1, ss.633093, 2023 (Scopus)

30. Is Serum Vasohibin-1 Level Associated with the Development of Kidney Disease in Diabetic Patients?

Tütüncü D., SEYİTHANOĞLU M., ŞAHİN M., ÖZTÜRK İ., GÜZEL F. B., EREN N., et al.

Turkish journal of nephrology (Online) , cilt.32, sa.2, ss.112-119, 2023 (ESCI, Scopus, TRDizin)

31. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Barratt J., Lafayette R., Kristensen J., Stone A., Cattran D., Floege J., et al.

Kidney International , cilt.103, sa.2, ss.391-402, 2023 (SCI-Expanded, Scopus)

32. Relationship between disease awareness and severity of kidney disease in autosomal dominant polycystic kidney disease patients

Dogan E., EREN N., ÖZCAN Ş. G., ALTUNÖREN O., Gungor O., DHEİR H., et al.

THERAPEUTIC APHERESIS AND DIALYSIS , cilt.27, sa.1, ss.117-122, 2023 (SCI-Expanded, Scopus)

33. Clinical and pathologic features of primary membranous nephropathy in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group

YILDIZ A., Ulu S., ORUÇ A., Ucar A. R., Ozturk S., Alagoz S., et al.

RENAL FAILURE , cilt.44, sa.1, ss.1048-1059, 2022 (SCI-Expanded, Scopus)

34. Trends of primary glomerular disease in Turkey: TSN-GOLD registry report

Gul C. B., Kucuk M., Ozturk S., Demir E., EREN N., Sumnu A., et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.54, sa.9, ss.2285-2294, 2022 (SCI-Expanded, Scopus)

35. Impact of COVID-19 lockdown on mood status: A comparison of hemodialysis and oncology patients

Alagoz S., EREN N., ÖZCAN Ş. G., Atli Z., Ozkul O., Belli H., et al.

THERAPEUTIC APHERESIS AND DIALYSIS , cilt.26, sa.4, ss.781-789, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

36. The Longitudinal Evolution of Post-COVID-19 Outcomes Among Hemodialysis Patients in Turkey

Ozturk S., TURGUTALP K., ARICI M., Gorgulu N., TONBUL H. Z., EREN N., et al.

KIDNEY INTERNATIONAL REPORTS , cilt.7, sa.6, ss.1393-1405, 2022 (SCI-Expanded, Scopus)

37. THE LONGITUDINAL EVOLUTION OF COVID-19 OUTCOMES AMONG HEMODIALYSIS PATIENTS: A NATIONWIDE MULTICENTRE CONTROLLED STUDY

Ozturk S., TURGUTALP K., ARICI M., Gorgulu N., TONBUL H. Z., EREN N., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.37, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. How Dialysis Patients Cope with a Curfew? A Comparison of Psychological Status between Hemodialysis and Peritoneal Dialysis Patients During the COVID-19 Pandemic

KARACA C., EREN N., DİNCER M. T., TURAN Ş., Karaca H. K., Kucuk M., et al.

BLOOD PURIFICATION , cilt.51, sa.5, ss.458-463, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. RELATIONSHIP BETWEEN DISEASE AWARENESS AND SEVERITY OF KIDNEY DISEASE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS

Dogan E., EREN N., ÖZCAN Ş. G., ALTUNÖREN O., Gungor O., DHEİR H., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.37, 2022 (SCI-Expanded, Scopus)

40. EVALUATION OF OUTCOMES OF PERITONEAL DIALYSIS PATIENTS IN THE POST-COVID-19 PERIOD: A NATIONAL MULTICENTER CASE-CONTROL STUDY FROM TURKEY

ÖZTÜRK S., Gursu M., Arici M., Sahin I., Eren N., Yilmaz M., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.37, 2022 (SCI-Expanded, Scopus)

41. Hearing Impairments as an Overlooked Condition in Kidney Transplant Recipients

Simsir M., Yildiz M. G., Karatas M., Dalgic A., Ozturk I., Tatar E., et al.

TRANSPLANT INTERNATIONAL , cilt.35, 2022 (SCI-Expanded, Scopus)

42. A comparison of antibody response in kidney transplant recipients and healthcare workers who had PCR-confirmed COVID-19 infection

DİNÇER M. T., EREN N., Murt A., YILDIZ N., ÖZCAN SOYSAL Ş. G., ERGÜL M., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.6, ss.1754-1761, 2022 (SCI-Expanded, Scopus, TRDizin)

43. Therapetic Plasmapheresis: A Retrospective Study; 12 Years of Single Center Experience

HANAZAY Y., GÖKÇAY BEK S., BAKIRDÖĞEN S., EREN N., DERVİŞOĞLU E., KALENDER GÖNÜLLÜ B.

Kocaeli Tıp Dergisi , cilt.11, 2022 (TRDizin)

44. Pregnancy and its outcomes in hemodialysis patients in Turkey

DHEİR H., Gungor O., Ulu M. S., Oguz E. G., EREN N., ALTUNÖREN O., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.2, ss.354-360, 2022 (SCI-Expanded, Scopus, TRDizin)

45. Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19

TURGUTALP K., Ozturk S., ARICI M., EREN N., Gorgulu N., Islam M., et al.

BMC NEPHROLOGY , cilt.22, sa.1, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. The relationship between glomerular IgG staining and poor prognostic findings in patients with IgA nephropathy: the data from TSN-GOLD working group

TURGUTALP K., Cebeci E., Turkmen A., DERİCİ Ü., SEYAHİ N., EREN N., et al.

BMC NEPHROLOGY , cilt.22, sa.1, 2021 (SCI-Expanded, Scopus)

47. Characteristics and outcomes of hospitalised older patients with chronic kidney disease and COVID-19: A multicenter nationwide controlled study

Ozturk S., TURGUTALP K., ARICI M., Gok M., Islam M., ALTIPARMAK M. R., et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.75, sa.9, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

48. Comparison of Therapeutic Plasma Exchange and Double Filtration Plasmapheresis: Five Year Experience of Nephrology Unit

GÖKÇAY BEK S., BAKIRDÖĞEN S., EREN N., HANAZAY Y., KALENDER GÖNÜLLÜ B.

Dicle Tıp Dergisi , cilt.3, sa.48, ss.523-528, 2021 (TRDizin)

49. Characteristics of primary glomerular diseases patients with hematuria in Turkey: the data from TSN-GOLD Working Group

Sumnu A., TÜRKMEN K., Cebeci E., Turkmen A., EREN N., Seyahi N., et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.53, sa.5, ss.945-954, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

50. Investigating the Effects of Fluorine Substituents on Organic Dyes in Dye-Sensitized Solar Cells

BERK S. G., Abdalhadi S., BAKIRDÖĞEN S., Mohmmed N., EREN N., thejeel k., et al.

Journal of the Turkish Chemical Society, Section A: Chemistry , cilt.48, sa.3, ss.1-10, 2021 (Scopus, TRDizin)

51. Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group

Aydin Z., TÜRKMEN K., Dede F., Yasar E., Ozturk S., Aydin M., et al.

CLINICAL AND EXPERIMENTAL NEPHROLOGY , cilt.25, sa.2, ss.173-183, 2021 (SCI-Expanded, Scopus)

52. Hepcidin and Vitamin D Levels: Mutual Effects in Anemia of Chronic Kidney Disease

ÜSTÜNER B., GÖKÇAY BEK S., EREN N., BAKIRDÖĞEN S., KALENDER GÖNÜLLÜ B.

Kocaeli Üniversitesi Sağlık Bilimleri Dergisi , cilt.7, sa.2, ss.110-114, 2021 (TRDizin)

53. Renal Tubular Acidosis in Patients with Systemic Lupus Erythematosus

Eren N., Gungor O., Sarisik F. N., Sokmen F., Tutuncu D., Cetin G. Y., et al.

KIDNEY & BLOOD PRESSURE RESEARCH , cilt.45, sa.6, ss.883-889, 2020 (SCI-Expanded, Scopus)

54. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey

ÖZTÜRK S., Turgutalp K., ARICI M., Odabas A. R., ALTIPARMAK M. R., Aydin Z., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.35, sa.12, ss.2083-2095, 2020 (SCI-Expanded)

55. Usefulness of Peritoneal Ultrafiltration in Patients with Diuretic Resistant Heart Failure without End-Stage Renal Disease

ŞAHİN E., GÖKÇAY BEK S., EREN N., KARAÜZÜM İ., ERGÜL M., YILDIZ N., et al.

CARDIORENAL MEDICINE , cilt.10, sa.6, ss.429-439, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

56. Can vasohibin-1, an endothelium-derived angiogenesis inhibitor, be a marker of endothelial dysfunction in hemodialysis patients?

ALTUNÖREN O., Kerkutluoglu M., Sarisik F. N., Akkus G., SEYİTHANOĞLU M., Doganer A., et al.

SEMINARS IN DIALYSIS , cilt.33, sa.5, ss.418-427, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

57. Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor?

Alagoz S., DİNCER M. T., EREN N., Bakir A., PEKPAK M., TRABULUS S., et al.

PLOS ONE , cilt.15, sa.4, 2020 (SCI-Expanded, Scopus)

58. Miyozin Agir Zincir 9 Iliskili Trombosit Bozuklugu: Zor Tani

GÖKÇAY BEK S., EREN N., ERGÜL M.

Kocaeli Tıp Dergisi , cilt.9, sa.1, ss.120-123, 2020 (TRDizin)

59. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases

Terzi D., Birtas A., Eren N., Gedük A., Mehtap Ö., Tarkun P., et al.

TUMORI JOURNAL , sa.6, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Ruilope L. M., Agarwal R., Anker S. D., Bakris G. L., Filippatos G., Nowack C., et al.

AMERICAN JOURNAL OF NEPHROLOGY , cilt.50, sa.5, ss.345-356, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

61. COMPARISON OF DIPPING/NON-DIPPING PATTERN WITH ATHEROGENIC DYSLIPIDEMIA IN GRADE 1 OBESE HYPERTENSIVE PATIENTS

Akin S., Aydin Z., Ozdemir P., Aladag N., Ozgur Y., EREN N.

ACTA MEDICA MEDITERRANEA , cilt.35, sa.6, ss.3343-3347, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

62. Fabry Disease Prevalence in Renal Replacement Therapy in Turkey

Yalin S. F., EREN N., Sinangil A., YILMAZ V. T., Tatar E., Ucarf A. R., et al.

NEPHRON , cilt.142, sa.1, ss.26-33, 2019 (SCI-Expanded, Scopus)

63. The Efficacy of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Population

ALTUNÖREN O., Gungor O., EREN N., Tanrisev M., Hur E., TÜRKMEN K., et al.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL , cilt.25, sa.2, ss.192-198, 2016 (ESCI, Scopus, TRDizin)

64. Is Nebivolol Really Effective in Preventing Contrast Induced Nephropathy?

Altunoren O., Balli M., EREN N., Tasolar H., Arpaci A., Caglayan C. E., et al.

KIDNEY & BLOOD PRESSURE RESEARCH , cilt.40, sa.5, ss.533-541, 2015 (SCI-Expanded)

65. Epicardial Adipose Tissue Thickness in Hemodialysis Patients

Altun B., TAŞOLAR M. H., Eren N., Binnetoglu E., ALTUN M., Temiz A., et al.

ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES , cilt.31, sa.8, ss.941-946, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. SYSTEMIC IMMUNE RESPONSE BEFORE AND AFTER TREATMENT OF HELICOBACTER PYLORI INFECTION

EREN N., ÖZGÜR O., Kartı S. S., Yılmaz M., Ukinc K., ALVER A., et al.

Yeditepe Medical Journal , 2013 (TRDizin)

67. Crimean-Congo hemorrhagic fever in Turkey

Karti S., Odabasi Z., Korten V., Yilmaz M., SÖNMEZ M., Caylan R., et al.

EMERGING INFECTIOUS DISEASES , cilt.10, sa.8, ss.1379-1384, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Effects of interferon-α-2a on Th3 cytokine response in multiple myeloma patients

SÖNMEZ M., SÖNMEZ B., Eren N., Yilmaz M., Karti S., Ovali E.

TUMORI JOURNAL , cilt.90, sa.4, ss.387-389, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

69. Leiomyosarcoma of the Uterus Presenting with Thrombotic Thrombocytopenic Purpura.

Kartı S. S., EREN N., SÖNMEZ M., Yılmaz M., ÇOBANOĞLU Ü., KAVGACI H., et al.

TURKISH JOURNAL OF HAEMATOLOGY , cilt.20, sa.3, ss.163-165, 2003 (Scopus)

70. Spontaneous bacterial empyema in cirrhosis

ÖZGÜR O., Kartı S. S., Yıldız B., EREN N.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.15, sa.1, ss.63-64, 2003 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 78